0000948320
false
0000948320
2023-07-11
2023-07-11
0000948320
LFMD:CommonStockParValue0.01PerShareMember
2023-07-11
2023-07-11
0000948320
LFMD:SeriesCumulativePerpetualPreferredStock0.0001PerShareMember
2023-07-11
2023-07-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 11, 2023
LIFEMD,
INC.
(Exact
name of Registrant as specified in its charter)
Delaware |
|
001-39785 |
|
76-0238453 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
236
Fifth Avenue, Fourth Floor
New
York, NY 10001
(Address
of principal executive offices, including zip code)
(866)
351-5907
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:
☐ |
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, par value
$0.01 per share |
|
LFMD |
|
The Nasdaq Global Market |
Series A Cumulative Perpetual
Preferred Stock, par value $0.0001 per share |
|
LFMDP |
|
The Nasdaq Global Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Long-Term
Incentive Awards
Effective
July 11, 2023, Chief Financial Officer Marc Benathen entered into a Second Amendment to
his Employment Agreement with LifeMD, Inc. (the “Company”). In exchange for the cancellation of stock options exercisable
for 200,000 shares of the Company’s common stock, which were granted pursuant to his Employment Agreement, and 250,000 performance
share units, which were granted pursuant to the First Amendment to his Employment Agreement, Mr. Benathen received the following awards
pursuant to the Second Amendment to his Employment Agreement: (i) 125,000 restricted shares of common stock, with 50,000 restricted shares
vesting on January 1, 2024; and 75,000 restricted shares vesting on January 1, 2025; (ii) 261,250 restricted shares of common stock vesting
upon achievement of net revenue and adjusted EBITDA margin milestones for the healthcare business over a four-year performance period;
and (iii) 150,000 restricted shares of common stock vesting based on personal performance over a two-year performance period. In addition,
vesting accelerated immediately on 25,000 restricted stock units previously granted to Mr. Benathen under the First Amendment to his
Employment Agreement.
Unvested
awards are forfeited in the event of a termination for “Cause,” as defined in the Employment Agreement. In the event of a
termination without “Cause” or for “Good Reason,” or in the event of a “Change of Control,” as defined
in the Employment Agreement, as amended, 100% of the awards vest immediately.
The
foregoing description of the long-term incentive awards does not purport to be complete and is qualified in its entirety by reference
to Mr. Benathen’s Employment Agreement and its First and Second Amendments, and the related Restricted Stock Award Agreement, which
are filed as exhibits to this Current Report on Form 8-K and incorporated herein by reference.
Item
9.01. Exhibits.
(d)
Exhibits
Exhibit
No. |
|
Exhibit |
10.1 |
|
Employment Agreement dated February 6, 2021 between Marc Benathen and LifeMD, Inc. (incorporated by reference from Exhibit 10.1 to the Current Report on Form 8-K filed February 10, 2021) |
10.2 |
|
First Amendment dated January 27, 2022 to the Employment Agreement between Marc Benathen and LifeMD, Inc. (incorporated by reference from Exhibit 10.1 to the Current Report on Form 8-K filed February 2, 2022) |
10.3 |
|
Second Amendment dated July 11, 2023 to the Employment Agreement between Marc Benathen and LifeMD, Inc. |
10.4 |
|
Restricted Stock Award Agreement dated July 11, 2023 between Marc Benathen and LifeMD, Inc. |
104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
LIFEMD,
INC. |
|
|
|
|
Dated: |
July
14, 2023 |
By: |
/s/
Eric Yecies |
|
|
|
Eric
Yecies |
|
|
|
General
Counsel and Chief Compliance Officer |
Exhibit
10.3
SECOND
AMENDMENT TO EMPLOYMENT AGREEMENT
THIS
SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of July 11, 2023 (the “Second
Amendment Effective Date”) by and between Marc Benathen, an individual and resident of the State of New York, (the “Employee”)
and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Corporation. The Employee and the
Company are also each hereinafter referred to individually as a “Party” and together as the “Parties”.
RECITALS
WHEREAS,
on February 6, 2021 (“Employment Agreement Effective Date”), the Company and the Employee entered into an Employment Agreement
(the “Employment Agreement”) whereby Employee was hired to serve the Company in the capacity as Chief Financial Officer,
with a base salary of $325,000, an equity grant of 200,000 options subject to monthly vesting over a period of 36 months, and 15,000
restricted shares (3,750 shares vesting immediately, and 11,250 shares (of which 7,500 shares have already vested) vesting in three equal
installments of 3,750 vesting on each of February 4, 2022, February 4, 2023, and February 4, 2024);
WHEREAS,
for avoidance of doubt, the remaining 3,750 shares will continue to vest on the original February 4, 2024 vesting date;
WHEREAS,
on January 27, 2022, the Company and the Employee entered into a First Amendment To The Employment Agreement (the “First Amendment”)
to: (i) increase the total equity compensation to include up to 75,0000 time-vested shares of the Company’s common stock (of which
50,000 shares have already vested) and up to 250,000 performance-based shares of the Company’s common stock, subject to vesting
upon the achievement of certain milestones as described in more detail therein; and (ii) add an express indemnification provision and
agreement.
WHEREAS,
on or about March 2, 2022, the Company changed Employee’s base salary to $425,000.
WHEREAS,
for avoidance of doubt, other than the amendments set forth below in this Second Amendment, all other provisions of the Employment Agreement
(as amended by the First Amendment) remain in effect today and moving further, unless and until amended in the future.
WHEREAS,
the Parties desire to further amend the Employment Agreement to: (i) cancel the 200,000 stock options previously awarded under Section
4(e) of the Employment Agreement (all of which carry a $21.02 exercise price and are underwater); (ii) accelerate the vesting the remaining
25,000 shares of time-vested RSUs previously awarded under the First Amendment to immediately vest, without restriction, on the Second
Amendment Effective Date; (iii) cancel the 250,000 restricted shares previously awarded under the First Amendment (none of which have
become earned and vested); and (iv) replace the cancelled awards (from sub-paragraphs (i) and (iii) above) with a new grant of 536,250
restricted shares of stock, and acceleration of vesting of 25,000 restricted shares of stock from the January 27, 2022 grant, subject
to vesting and other terms as described below.
NOW
THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Parties hereby agree as follows:
1. Preamble.
| a. | The
January 27, 2022 grant of 75,000 restricted shares (of which 50,000 shares have already vested)
remains effective. |
| b. | The
remaining 25,000 restricted shares hereby immediately vest, without restriction (other than
any applicable Rule 144 restriction), on this Second Amendment Effective Date. |
| c. | Both
the 200,000 stock options previously awarded under Section 4(e) of the Employment Agreement
and the 250,000 restricted shares previously awarded under the First Amendment are hereby
cancelled. |
2. Amendments.
The Employment Agreement shall be further amended as follows, in accordance with the terms and conditions of Section 8 thereof:
| a. | Section
4(e) of the Employment Agreement is hereby added: |
4(e) Replacement
of Stock Option and Long-Term Equity Incentive. In exchange for the cancellation of the 200,000 stock options previously granted
under Section 4(e) of the Employment Agreement and the 250,000 restricted shares previously granted under Section 4(e) [sic] of the
First Amendment, pursuant to the Company’s 2020 Equity and Incentive Plan (the “Plan”) and any amendments thereto,
Employee shall receive, upon the Second Amendment Effective Date, a new award of 536,250 restricted shares of the Company’s
common stock, and acceleration of vesting of 25,000 restricted shares of stock from the January 27, 2022 grant (collectively, the
“Restricted Shares”) with:
(i)
150,000 restricted shares vesting as follows:
| ● | 25,000
restricted shares immediately vest on the Second Amendment Effective Date (i.e., accelerated
from the January 27, 2022 grant); |
| ● | 50,000
restricted shares vest on January 1, 2024; and |
| ● | 75,000
restricted shares vest on January 1, 2025; |
and
an additional 411,250 restricted shares vesting upon achievement of the performance and milestones described below:
| ● | 87,000
restricted shares vest upon the healthcare business achieving $100,000,000 in net revenue
(defined as gross healthcare sales minus healthcare-related refunds and returns) with a 5%
adjusted EBITDA margin, on or before December 31, 2025; |
| ● | 87,000
restricted shares vest upon the healthcare business achieving $150,000,000 in net revenue
with a 10% adjusted EBITDA margin, on or before December 31, 2026; |
| ● | 87,250
restricted shares vest upon the healthcare business achieving $200,000,000 in net revenue
with a 10% adjusted EBITDA margin, on or before December 31, 2027; |
| ● | 75,000
restricted shares vest on 3/1/24 based on the performance of Employee in the 2023 calendar
year, at the discretion of the CEO and approval by the Board of Directors; and |
| ● | 75,000
restricted shares vest on 3/1/25 based on the performance of Employee in the 2024 calendar
year, at the discretion of the CEO and approval by the Board of Directors. |
Except
as otherwise set forth herein or in the associated Restricted Stock Agreement, vesting of the Restricted Shares will cease upon the termination
of Employee’s employment with the Company for cause subject to the terms of the Employment Agreement and any amendments thereto.
All Restricted Shares vest immediately and become exercisable in full upon a Change in Control, regardless of whether or not any performance
milestone has been met at the time of the Change in Control. As used herein, “Change of Control” means (i) a bona fide transfer
or series of related transfers of Shares to any person or Group in which, or as a result of which, such person or Group obtains the direct
or indirect right to elect a majority of the board of directors of the Company; or (ii) a sale of all or substantially all of the assets
of the Company. As used herein, “Group” means any group or syndicate that would be considered a “person” for
purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. The foregoing grant of Restricted Shares shall be made
on the Company’s customary form of restricted stock award for employees. All applicable awards under this Second Amendment shall
be subject to forfeiture or other penalties under any clawback or recoupment policy of the Company in effect from time to time.
3. Governing
Law; Jurisdiction. This Second Amendment shall be governed by and construed in accordance with the internal laws of the State of
New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).
Any legal proceeding arising out of or based upon this Second Amendment shall be instituted in the federal courts or the courts of the
State of New York and each party irrevocably submits to the exclusive jurisdiction of such courts in any such proceeding.
4. Counterparts.
This Second Amendment may be executed in several counterparts, each of which shall be deemed to be an original copy and all of which
together shall constitute one agreement binding on all parties hereto, notwithstanding that all the parties shall not have signed the
same counterpart.
[signature
on next page]
IN
WITNESS WHEREOF, each of the undersigned hereby (a) executes this Second Amendment to the Employment Agreement provided herein(b)
confirms its agreement with the provisions and covenants herein provided; and (c) agrees to be bound by this Second Amendment to the
Employment Agreement.
EXECUTED
as of the Second Amendment Effective Date, as set forth above.
LIFEMD,
INC.
/s/ Justin Schreiber |
|
By:
|
Justin
Schreiber, Chairman & CEO |
|
|
|
|
EMPLOYEE |
|
|
|
|
/s/ Marc Benathen |
|
By:
|
Marc
Benathen, Chief Financial Officer |
|
Exhibit
10.4
LIFEMD,
INC.
RESTRICTED
STOCK AWARD AGREEMENT
THIS
AGREEMENT (this “Agreement”) is made effective as of July 11, 2023 (the “Grant Date”) between LifeMD,
Inc. (the “Company”) and Marc Benathen (the “Employee”).
WHEREAS,
the Company desires to grant the Employee, shares of the Company’s Common Stock, $0.01 par value (“Shares”),
subject to certain restrictions as set forth in this Agreement (this “Restricted Stock Award”), pursuant to the LifeMD,
Inc. 2020 Equity Incentive Plan (the “Plan”) and any Amendments thereto (capitalized terms not otherwise defined herein
shall have the same meanings as in the Plan);
WHEREAS,
the Board of Directors (the “Board”) has determined that it would be to the advantage and best interest of the
Company and its stockholders to grant the Shares herein to the Employee; and
NOW
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
1.
Grant of Restricted Shares. Subject to the terms and conditions of the Plan and the additional terms and conditions set forth
in this Agreement, the Company hereby grants to the Employee a new award of 536,250 restricted shares, and reflects and acceleration
of 25,000 restricted shares from the January 27, 2022 grant (collectively, the “Restricted Shares”). The Restricted Shares
shall vest in accordance with Section 2 hereof.
2.
Vesting. The Restricted Shares shall vest as follows:
| ● | 25,000
restricted shares immediately vest on the Second Amendment Effective Date (i.e., accelerated
from the January 27, 2022 grant); |
| ● | 50,000
restricted shares vest on January 1, 2024; |
| ● | 75,000
restricted shares vest on January 1, 2025; |
| ● | 87,000
restricted shares vest upon the healthcare business achieving $100,000,000 in net revenue
(defined as gross healthcare sales minus healthcare-related refunds and returns) with a 5%
adjusted EBITDA margin, on or before December 31, 2025; |
| ● | 87,000
restricted shares vest upon the healthcare business achieving $150,000,000 in net revenue
with a 10% adjusted EBITDA margin, on or before December 31, 2026; |
| ● | 87,250
restricted shares vest upon the healthcare business achieving $200,000,000 in net revenue
with a 10% adjusted EBITDA margin, on or before December 31, 2027; |
| ● | 75,000
restricted shares vest on 3/1/24 based on the performance of Employee in the 2023 calendar
year, at the discretion of the CEO and approval by the Board of Directors; and |
| ● | 75,000
restricted shares vest on 3/1/25 based on the performance of Employee in the 2024 calendar
year, at the discretion of the CEO and approval by the Board of Directors. |
(a)
To the extent it is then unvested, the Restricted Shares shall vest upon the termination of the Employee’s employment with the
Company without Cause (if termination is by the Company) or for Good Reason (if termination is by Employee), as such terms are defined
in the employment agreement of such Employee or if such term or terms is not defined in the employment agreement or there is not an employment
agreement, as defined by the Plan. If applicable, in lieu of fractional vesting, the number of Restricted Shares shall be rounded up
each time until fractional Restricted Shares are eliminated.
(b)
However, notwithstanding any other provisions of this Agreement, at the option of the Board in its sole and absolute discretion, all
Restricted Shares shall be immediately forfeited in the event any of the following events occur:
(i)
The Employee purchases or sells securities of the Company without written authorization in accordance with the Company’s insider
trading policy then in effect, if any;
(ii)
The Employee (A) discloses, publishes, or authorizes anyone else to use, disclose, or publish, without the prior written consent of the
Company, any proprietary or confidential information of the Company, including, without limitation, any information relating to existing
or potential customers, business methods, financial information, trade or industry practices, sales and marketing strategies, employee
information, vendor lists, business strategies, intellectual property, trade secrets, or any other proprietary or confidential information
or (B) directly or indirectly uses any such proprietary or confidential information for the individual benefit of the Employee or the
benefit of a third party;
(iii)
During the term of employment and for a period of two (2) years thereafter, the Employee disrupts or damages, impairs, or interferes
with the business of the Company or its Affiliates by recruiting, soliciting, or otherwise inducing any of their respective employees
to enter into employment or other relationship with any other business entity, or terminate or materially diminish their relationship
with the Company or its Affiliates, as applicable;
(iv)
During the term of employment and for a period of one (1) year thereafter, the Employee solicits or directs business of any person or
entity who is (A) a customer of the Company or its Affiliates at any time or (B) solicited to be a “prospective customer”
of the Company or its Affiliates, in any case either for such Employee or for any other person or entity. For purposes of this clause
(v), “prospective customer” means a person or entity who contacted, or is contacted by, the Company or its Affiliates regarding
the provision of services to or on behalf of such person or entity; provided that the Employee has actual knowledge of such prospective
customer;
(v)
The Employee fails to reasonably cooperate to effect a smooth transition of the Employee’s duties and to ensure that the Company
is apprised of the status of all matters the Employee is handling to the extent commercially and reasonably possible and not otherwise
prevented or restricted by a future employer of Employee, or is unavailable for consultation after termination of employment of the Employee,
if such availability is a condition of any agreement to which the Company and the Employee are parties;
(vi)
The Employee fails to assign all of such Employee’s rights, title, and interest in and to any and all ideas, inventions, formulas,
source codes, techniques, processes, concepts, systems, programs, software, computer data bases, trademarks, service marks, brand names,
trade names, compilations, documents, data, notes, designs, drawings, technical data, and/or training materials, including improvements
thereto or derivatives therefrom, whether or not patentable or subject to copyright or trademark or trade secret protection, developed
and produced by the Employee used or intended for use by or on behalf of the Company or the Company’s clients;
(vii)
The Employee acts in a disloyal manner to the Company, such as making comments, whether oral or in writing, that tend to disparage or
injure: (i) the reputation or business of the Company or its Affiliates, or is likely to result in discredit to, or loss of, business
reputation or goodwill of the Company or its Affiliates or (ii) its directors, officers, or stockholders; or
(viii)
A finding by the Board that the Employee has acted against the interests of the Company or in a manner that has or may have a detrimental
effect on the Company.
In
addition, all of the Restricted Shares shall, to the extent it is then unvested, vest immediately prior to the closing for any Change
of Control. As used herein, “Change of Control” means: (i) a bona fide transfer or series of related transfers
of Shares to any person or Group in which, or as a result of which, such person or Group obtains the direct or indirect right to elect
a majority of the board of directors of the Company; or (ii) a sale of all or substantially all of the assets of the Company. As used
herein, “Group” means any group or syndicate that would be considered a “person” for purposes of Section
13(d) of the Securities Exchange Act of 1934, as amended.
(c)
For purposes of this Agreement, “Affiliate” means with respect to a person or entity, any other person or entity controlled
by, in control of, or under common control with such person or entity, and “controlled,” “controlled by,” and
“under common control with” shall mean direct or indirect possession of the power to direct or cause the direction of management
policies (whether through ownership of voting securities, by contract, or otherwise, of a person or entity.
3.
Representations and Warranties; Acknowledgements. In connection with the grant of the Restricted Shares hereunder, Employee represents
and warrants to the Company that:
(a)
Employee is acquiring Restricted Shares for Employee’s own account, not as a nominee or agent, for investment only and not with
a view towards, or for resale in connection with, the public sale or distribution thereof.
(b)
Employee understands that: (a) the Restricted Shares have not been registered under the Securities Act of 1933 as amended (the “Securities
Act”), or any state securities laws, and may not be offered for sale, sold, assigned, or transferred unless (A) subsequently
registered thereunder or (B) sold in reliance on an exemption therefrom; and (b) neither the Company nor any other person is under any
obligation to register such securities under the Securities Act or any state securities laws or to comply with the terms and conditions
of any exemption thereunder. In this regard, Employee represents that Employee is familiar with SEC Rule 144, and understands the resale
limitations imposed thereby and by the Securities Act.
(c)
Employee is able to bear the economic risk of Employee’s investment in the Shares for an indefinite period of time because the
Restricted Shares have not been registered under the Securities Act and, therefore, cannot be sold unless subsequently registered under
the Securities Act or an exemption from such registration is available.
(d)
Employee and Employee’s advisers have had an opportunity to ask questions and receive answers concerning the terms and conditions
of the offering of the Shares as Employee and Employee’s advisers have requested and have had full and free access and opportunity
to inspect, review, examine, and inquire about such other information concerning the Company and its Affiliates as they have requested.
Employee and Employee’s advisers have also been provided an opportunity to review and ask questions about the Plan.
(e)
Employee has had an opportunity to consult with independent legal counsel regarding Employee’s rights and obligations under this
Agreement and the Plan, and fully understands the terms and conditions contained herein. Employee is not relying on the Company or any
of its employees, agents, or representatives with respect to the legal, tax, economic, and related considerations of an investment in
the Shares. Employee understands that in the future the Shares may significantly increase or decrease in value, and the Company has not
made any representation to the Employee about the potential future value of the Restricted Shares.
(f)
Employee understands and agrees that the investment in the Company involves a high degree of risk and that no guarantees have been made
or can be made with respect to the future value of the Restricted Shares or the future profitability or success of the Company.
4.
Termination of Relationship. Subject to Paragraph 2(a), upon the termination of employment, all unvested Shares of Restricted
Shares shall be automatically and irrefutably forfeited. If such forfeiture occurs, Employee shall execute and deliver to the Company
any and all further documents (including an Assignment Separate From Certificate) as the Company reasonably requests to further document
the forfeiture. As used in this Agreement, “employment”, “employ”, and like terms shall be construed
to include any employment or consulting relationship with the Company or its Affiliates. For purposes of this Agreement, a change from
such an employment relationship to such a consulting relationship or a relationship as a member of the Board or vice versa shall not
be treated as a termination of employment.
5.
Redemption. If any of the events specified in Section 2(b) of this Agreement occur within the time periods set forth therein,
and subject to the option of the Board in its sole and absolute discretion to enforce any such event as a breach of this Agreement, all
Restricted Shares that vested during the applicable timer periods shall be forfeited and forthwith, as necessary, surrendered by the
Employee to the Company within ten (10) days after the Employee receives written demand from the Company for such Restricted Shares.
6.
Certificates. Certificates—which may be in electronic book entry format or other format used by the Company in ordinary
course of doing business—evidencing the Restricted Shares shall be issued by the Company and shall be registered in the Employee’s
name promptly after the date the shares are vested. No certificates shall be issued for fractional shares, but rather rounded up to the
next whole share.
7.
Rights as a Stockholder. Neither the Employee, the Employee’s estate, nor the Transferee have any rights as a shareholder
with respect to any Common Stock covered by the Restricted Shares unless and until such Restricted Shares have vested. “Transferee”
shall mean an individual to whom such Employee’s vested Restricted Shares are transferred by will or by the laws of descent and
distribution.
8.
Legend on Certificates. The Certificates representing the vested Restricted Shares delivered to the Employee as contemplated by
Section 6 shall bear such legends, and be subject to such stop transfer orders, as the Company may deem advisable to give notice of restrictions
imposed by this Agreement, the Plan, the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock
exchange upon which such Shares are listed, or any applicable law. The Company may cause a legend or legends to be put on any such certificates
to make appropriate reference to such restrictions.
9.
Transferability. To the extent that the Restricted Shares are then unvested, Employee shall not transfer, sell, assign, pledge,
hypothecate, or otherwise dispose of the Restricted Shares.
10.
Employment by the Company. Nothing contained in this Agreement or in any other agreement entered into by the Company and the Employee
contemporaneously with the execution of this Agreement (i) shall be deemed to obligate the Company or any of its Affiliates to employ
the Employee in any capacity whatsoever, or (ii) shall prohibit or restrict the Company or any of its Affiliates from terminating the
employment, if any, of the Employee at any time or for any reason whatsoever, and the Employee hereby acknowledges and agrees that neither
the Company nor any other Person has made any representations or promises whatsoever to the Employee concerning the Employee’s
employment or continued employment by the Company.
11.
Sale of Shares Acquired. Any shares of the Company’s Common Stock acquired pursuant to Restricted Stock Awards granted hereunder
cannot be sold by the Employee, subject to registration or an exemption from registration such as to Rule 144 promulgated under the Securities
Act, until at least six (6) months elapse from the date of grant of this Restricted Stock Award, except in the case of death or disability
or if the grant was exempt from the short-swing profit provisions of Section 16(b).
12.
Withholding. The Employee acknowledges that the Employee is responsible for all liability for applicable tax related to the issuance
or vesting of this Restricted Stock Award. Unless Employee uses a designated broker to sell Shares with an aggregate fair market value
sufficient to cover the amount required to be withheld by the Company, or the Employee delivers in cash or certified check the amount
required to be withheld by the Company, the Company will issue the number of Shares owed to the Employee under this Restricted Stock
Award less a number of Shares equal to, in the aggregate, the amount of applicable tax related to the delivery of such Shares.
13.
Adjustments. The Restricted Shares under this Agreement shall be subject to the terms of the Plan, including but not limited to
Section 3(b) (Changes in Stock) and 3(c) (Sale Events) of the Plan.
14.
Limitation on Obligations. The Company’s obligation with respect to the Restricted Shares granted hereunder is limited solely
to the delivery to the Employee of Shares on the date when such Shares are due to be delivered hereunder, and in no way shall the Company
become obligated to pay cash in respect of such obligation. This Restricted Stock Award shall not be secured by any specific assets of
the Company, nor shall any assets of the Company be designated as attributable or allocated to the satisfaction of the Company’s
obligations under this Agreement. In addition, the Company shall not be liable to the Employee for damages relating to any delays in
issuing the share certificates to him/her (or his/her designated entities), any loss of the certificates, or any mistakes or errors in
the issuance of the certificates or in the certificates themselves.
15.
Securities Laws. Upon the vesting of any Restricted Shares, the Company may require the Employee to make or enter into such written
representations, warranties, and agreements as the Committee may reasonably request in order to comply with applicable securities laws
or with this Agreement. The granting of the Restricted Shares hereunder shall be subject to all applicable laws, rules, and regulations
and to such approvals of any governmental agencies as may be required.
16.
Arbitration. Any controversy, dispute or claim arising out of or relating to this Agreement, or its interpretation, application,
implementation, breach, or enforcement which the parties hereto are unable to resolve by mutual agreement, shall be settled by submission
by either party of the controversy, claim, or dispute to binding arbitration in New York County, New York (unless the parties agree in
writing to a different location), before a single arbitrator in accordance with the rules of the American Arbitration Association then
in effect. The decision and award made by the arbitrator shall be final, binding, and conclusive on all parties hereto for all purposes,
and judgment may be entered thereon in any court having jurisdiction thereof.
17.
Governing Law. This Agreement and any dispute, disagreement, or issue of construction or interpretation arising hereunder whether
relating to its execution, its validity, the obligations provided herein or performance, shall be governed or interpreted according to
the laws of the State of Delaware without regard to choice of law considerations.
18.
Restricted Stock Award Subject to Plan. This Restricted Stock Award shall be subject to the terms and provisions of the Plan.
In the event of any conflict between this Agreement and the Plan, the terms of this Agreement shall control.
19.
Signature in Counterparts. This Agreement may be signed in multiple counterparts, each of which shall be deemed an original and
all of which taken together shall be deemed one and the same instrument.
20.
Copy of Plan. By execution of this Agreement, Employee acknowledges receipt of a copy of the Plan.
21.
New Shares.
(a)
Any shares of capital stock of the Company or any successor thereto (“New Shares”) issued by the Company from time
to time (including without limitation in any stock split or stock dividend) with respect to Restricted Shares (“Old Shares”)
shall also be treated as Restricted Shares for all purposes of this Agreement.
(b)
The New Shares so issued shall at all times be vested in the same proportion as the Old Shares are vested. For example: (i) if none of
the Old Shares are vested as of the date that the New Shares are issued, then none of the New Shares will be vested when issued, (ii)
if, from time to time, 25% of the Old Shares become vested at any later date, then 25% of the New Shares shall also become vested on
that date; and (ii) if all of the Old Shares are vested on a date, then all of the New Shares shall be vested on that date.
(c)
The New Shares shall be subject to this Agreement, including without limitation Section 3 thereof, to the same extent as the Old Shares.
[signature
on next page]
IN
WITNESS WHEREOF, the parties hereto have executed this Restricted Stock Award Agreement as of the date first above written.
|
COMPANY: |
|
|
|
LIFEMD,
INC. |
|
|
|
/s/
Justin Schreiber |
|
Justin
Schreiber |
|
Chief
Executive Officer & Chairman of the Board |
|
EMPLOYEE: |
|
|
|
|
/s/
Marc Benathen |
|
Marc Benathen |
|
|
|
|
Email: |
|
|
Address: |
|
v3.23.2
Cover
|
Jul. 11, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jul. 11, 2023
|
Entity File Number |
001-39785
|
Entity Registrant Name |
LIFEMD,
INC.
|
Entity Central Index Key |
0000948320
|
Entity Tax Identification Number |
76-0238453
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
236
Fifth Avenue
|
Entity Address, Address Line Two |
Fourth Floor
|
Entity Address, City or Town |
New
York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10001
|
City Area Code |
(866)
|
Local Phone Number |
351-5907
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Common Stock, par value $0.01 per share |
|
Title of 12(b) Security |
Common Stock, par value
$0.01 per share
|
Trading Symbol |
LFMD
|
Security Exchange Name |
NASDAQ
|
Series Cumulative Perpetual Preferred Stock 0. 0001 Per Share [Member] |
|
Title of 12(b) Security |
Series A Cumulative Perpetual
Preferred Stock, par value $0.0001 per share
|
Trading Symbol |
LFMDP
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
LifeMD (NASDAQ:LFMDP)
Historical Stock Chart
From Apr 2024 to May 2024
LifeMD (NASDAQ:LFMDP)
Historical Stock Chart
From May 2023 to May 2024